Safety and efficacy of nonacog alfa for the treatment of haemophilia B in children younger than 6 years of age in a routine clinical care setting: the EUREKIX registry study.
Riana LiesnerNadine G AnderssonTony FriskElena SantagostinoMartin SchulzLisa YoungPaola GiordanoAnnarita TagliaferriPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2020)
Overall, nonacog alfa treatment effectively controlled bleeding events, with no new safety signals identified. These data support the safety and efficacy of nonacog alfa in routine clinical settings in children aged <6 years.